1 active not recruiting, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
Follow MEDI-570: new trials by email Literature Review of MEDI-570 trials Research Report on MEDI-570
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Anti-ICOS Monoclonal Antibody MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2016-09-13 | 2026-10-26 |
| A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus Placebo, MEDI-570 0.03 MG, MEDI-570 0.1 MG - Lupus Erythematosus, Systemic | Phase 1 | Terminated | MedImmune LLC | 44 | 2010-05-01 | 2014-08-26 |
Lupus Erythematosus, Systemic (1) · Lymphoma, Follicular (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1)
MedImmune LLC (1) · National Cancer Institute (NCI) (1)
Canada (2) · United States (2) · Mexico (1) · Peru (1) · South Africa (1)
David Close, PhD (1) · Julio C Chavez (1)
UM1CA186644 (1)